RxDoctor Payments Data

Malia Sering, PA

Medical · Oceanside, CANPI 1013198720

Payments from drug & device makers

$11,283in general payments, 2019–2025

Across 505 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Amgen$1K
  • EPI Health, LLC$1K
  • Sanofi$935
  • Johnson & Johnson$678
  • plus $4K from 19 others

What the payments were for

  • Consulting fees$1,53614%
  • Food & beverage$9,35183%
  • Education$3964%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,283 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$225,691
Medicare patients
706
Services billed
4,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab31$124,267
OtezlaApremilast19$90,046
Fluorouracil61$4,626
Clobetasol Propionate86$2,684
Fluocinonide58$2,454
Tretinoin49$2,334
Tacrolimus16$2,077
Triamcinolone Acetonide89$1,163
Metronidazole12$646
Econazole Nitrate20$640
Clindamycin Phosphate32$615
Desonide19$548
Ketoconazole51$531
Fluconazole15$405
Ciclopirox18$395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,171$90,04619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.

Other medical in Oceanside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →